Drug class in one race
NKG2A drugs for Non-Small Cell Lung Cancer
2 tracked NKG2A drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the NKG2A page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 31 Phase 2
Head-to-head evidence: BMS-986315 vs Monalizumab